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        Introduction 
  Myogenesis is a highly ordered and balanced process, which 
includes myoblast proliferation, cell cycle withdrawal, differen-
tiation, and cell fusion (  Buckingham et al., 2003  ). This process 
is regulated by a variety of hormones and growth factors. Insulin-
like growth factors (IGFs), including IGF-I and IGF-II, play 
critical roles in skeletal muscle differentiation and growth, as 
well as adult muscle regeneration and hypertrophy (  Musaro 
et al., 2001  ,   2004  ). Mice defi  cient in IGF ligand or IGF-I receptor 
exhibit muscle hypoplasia and die shortly after birth due to 
impaired muscle mass to infl  ate their lungs (  Liu et al., 1993  ; 
  Powell-Braxton et al., 1993  ). Transgenic mice with overexpression 
of IGF-I in muscle have larger muscle fi  bers and enhanced mus-
cle strength during aging (  Coleman et al., 1995  ;   Barton-Davis 
et al., 1998  ;   Barton et al., 2002  ;   Kaspar et al., 2003  ). In cultured 
muscle cells, IGF-II levels increase dramatically during myo-
genesis. IGF-II antisense oligonucleotides can abolish differen-
tiation (  Florini et al., 1991  ,   1993  ), and IGF-II overexpression 
accelerates myoblast differentiation (  Stewart et al., 1996  ). 
  Although most growth factors stimulate myoblast prolifer-
ation and inhibit myogenic differentiation, IGFs are unique in 
that they not only stimulate myoblast proliferation but also pro-
mote myogenic differentiation, two mutually exclusive processes 
(  Florini et al., 1996  ). These actions are mediated through the 
IGF-I receptor (IGF-IR), a transmembrane tyrosine kinase, and 
activation of the IGF-IR initiates downstream signaling cascades 
including the phosphatidylinositol 3-kinase (PI3K)-Akt path-
way. Earlier studies have shown that there is a temporal separa-
tion between these two responses to IGFs: IGF treatment causes 
a proliferative response in the fi  rst 24  –  36 h, and this is followed 
by subsequent increase in myogenic differentiation. The increase 
in differentiation is not secondary to increased cell number after 
IGF treatment (  Florini et al., 1996  ).   Rosenthal and Cheng (1995)   
have reported a biphasic effect of IGF-I on pRb, a regulator of 
cell cycle progression that is present in the hyperphosphorylated 
state during cell proliferation and hypophosphorylated state dur-
ing differentiation. They found that IGF treatment resulted in 
persistent Rb hyperphosphorylation for over 24 h before hypo-
phosphorylation became the dominant form. Several laboratories 
have shown that activation of PI3K, Akt, and FoxO promotes myo-
genic differentiation and survival (  Engert et al., 1996  ;   Kaliman 
  I
GF-II stimulates both mitogenesis and myogenesis 
through its binding and activation of the IGF-I receptor 
(IGF-IR). How this growth factor pathway promotes these 
two opposite cellular responses is not well understood. 
We investigate whether local IGF binding protein-5 (IGFBP-5) 
promotes the myogenic action of IGF-II. IGFBP-5 is induced 
before the elevation of IGF-II expression during myogene-
sis. Knockdown of IGFBP-5 impairs myogenesis and sup-
presses IGF-II gene expression. IGF-II up-regulates its own 
gene expression via the PI3K-Akt signaling pathway. 
Adding IGF-II or constitutively activating Akt rescues the 
IGFBP-5 knockdown-caused defects. However, an IGF 
analogue that binds to the IGF-IR but not IGFBP has only 
a limited effect. When added with low concentrations of 
IGF-II, IGFBP-5 restores IGF-II expression and myogenic 
differentiation, whereas an IGF binding  –  deﬁ  cient IGFBP-5 
mutant has no effect. These ﬁ  ndings suggest that IGFBP-5 
promotes muscle cell differentiation by binding to and 
switching on the IGF-II auto-regulation loop.
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 Interestingly, knockdown of IGFBP-5 suppresses IGF-II expression 
and reduces IGF-IR  –  mediated signaling activity. Further mech-
anistic analyses suggest that IGFBP-5 promotes muscle cell 
differentiation by binding to IGF-II and enhances the IGF-II 
autocrine regulatory loop. 
  Results 
  Induction of IGFBP-5 precedes the 
induction of IGF-II during myogenesis 
  C2C12 myoblasts undergo terminal differentiation after switch-
ing to horse serum containing differentiation medium (DM). 
As shown in  Fig. 1 A , at 24 h after the induction of differentiation, 
the expression of IGFBP-5 mRNA showed an approximate seven-
fold increase over the 0 h control (P   <   0.05). There was a fur-
ther increase (approximately fi  vefold) at 48 h. Thereafter, the 
IGFBP-5 mRNA levels decreased considerably, but remained 
higher than 0 h. In comparison, while the absolute IGF-II mRNA 
level (copy number/  μ  l) remained extremely low, the relative lev-
els of IGF-II mRNA increased dramatically at 48 h (51-fold 
over 24 h, P   <   0.05). There was a further approximate fourfold 
et al., 1996  ;   Coolican et al., 1997  ;   Jiang et al., 1999  ;   Rommel 
et al., 1999  ,   2001  ;   Lawlor and Rotwein, 2000a  ,  b  ;   Lawlor et al., 
2000  ;   Wilson et al., 2004  ;   Wilson and Rotwein, 2007  ). Rotwein 
and colleagues have reported that in cultured muscle cells, se-
creted IGF-II stimulates the IGF-IR, PI3K, and Akt to induce the 
expression of the cyclin-dependent kinase inhibitor p21 and 
Myogenin, and through this mechanism, maintains myoblast vi-
ability during early myogenesis (  Lawlor and Rotwein, 2000a  ,  b  ; 
  Lawlor et al., 2000  ;   Wilson et al., 2004  ;   Wilson and Rotwein, 
2007  ). Despite these advances in various intracellular signaling 
mechanisms underlying IGF actions in myogenesis, it remains 
puzzling how the activation of the same IGF-IR by the same 
ligand (IGF-II) can elicit opposite biological responses. 
  We now understand that most, if not all IGFs in the extra-
cellular environment are bound to IGF binding proteins (IGFBPs). 
IGFBPs are a family of secreted proteins that specifi  cally bind 
IGFs with affi  nities that are equal to or greater than those of 
the IGF-IR. Six distinct IGFBPs, designated as IGFBP-1 to -6, 
have been isolated and characterized in humans and a variety of 
other vertebrate species (  Clemmons, 2001  ;   Duan, 2002  ;   Firth 
and Baxter, 2002  ). IGFBP-5, the most conserved IGFBP, is the 
major protein secreted by skeletal muscles. IGFBP-5 is expressed 
in the myotomal compartments during early development in ro-
dent and zebrafi  sh (  Green et al., 1994  ;   Wood et al., 2005  ) and its 
expression is induced during muscle differentiation (  James et al., 
1993  ). In cultured myoblasts, IGFBP-5 expression levels in-
creased dramatically during myogenic differentiation (  Rotwein 
et al., 1995  ;   Bayol et al., 2000  ). These fi  ndings suggest that 
IGFBP-5 may play a role in modulating the actions of IGF-II 
on muscle differentiation. The precise role(s) of IGFBP-5 in 
myogenesis, however, remains under debate. Knockout of the 
IGFBP-5 in mice had a minimal effect on muscle size and whole 
body size, but IGFBP-3, -4, and -5 triple knockout mice showed 
smaller body size and reduced quadriceps muscles (  Ning et al., 
2006  ), indicating the potential compensatory effects from other 
IGFBPs in the single knockout mice. When overexpressed in vivo 
in transgenic mice (  Salih et al., 2004  ) and in vitro in cultured 
murine muscle cells under the control of a constitutive pro-
moter (  James et al., 1996  ;   Cobb et al., 2004  ;   Mukherjee et al., 
2007 ), IGFBP-5 inhibits muscle differentiation. When exogenous 
IGFBP-5 was added to cultured rat myoblasts together with IGF-I 
at an appropriate ratio, it stimulated IGF-I  –  induced differentia-
tion (  Ewton et al., 1998  ). Although these gain-of-function studies, 
either adding large amounts of purifi  ed IGFBP-5 to or stably and 
constitutively overexpressing of IGFBP-5 in cultured myoblasts, 
are useful in demonstrating the biological capabilities of IGFBP-5, 
they do not necessarily provide insight into the physiological 
function(s) of the endogenous protein. Furthermore, inter-
pretation of these data are not always straightforward because the 
IGFBP-5 expression is dramatically induced during myogenesis. 
  The objective of this study is to investigate the physiologi-
cal role(s) of endogenous IGFBP-5 in regulating IGF-II actions 
in skeletal muscle differentiation. Our results suggest the induc-
tion of IGFBP-5 precedes that of IGF-II in cultured C2C12 myo-
blast cells and in primary skeletal muscle cells. Knockdown 
of IGFBP-5 impairs myogenic differentiation and reduces 
the expression of Myogenin and myosin heavy chain (MHC). 
  Figure 1.       The induction of IGFBP-5 precedes that of IGF-II during myogenesis.   
Cultured C2C12 myoblasts were induced to differentiate by switching 
to differentiation medium (DM). Total RNA was extracted at different time 
points. IGFBP-5 mRNA (A) and IGF-II mRNA (B) levels were measured by 
qRT-PCR. Values are expressed as relative levels to that of 24 h for IGF-II 
(IGF-II mRNA levels were under the detection limit at 0 h) or to that of the 
0 h group for IGFBP-5 after normalized to cyclophilin levels. Data shown are 
means   ±   SE of three independent experiments. *, P   <   0.05, compared with 
the 0 h group;   †  , P   <   0.05, compared with the 24-h group;     , P   <   0.05, 
compared with the 48 h group.     981 IGFBP-5 PROMOTES THE MYOGENIC ACTION OF IGF-II   • Ren et al. 
remained as individual mononucleated cells (  Fig. 2 C  ). We ex-
amined the expression of MHC by immunostaining and Western 
blot. Both assays showed a dramatic decrease in MHC expres-
sion in the pSUPER-BP5  –  transfected cells (  Fig. 2, D and E  ). 
Quantifi  cation of Western blot data from four independent ex-
periments showed that the MHC levels were decreased by 84.4% 
(P   <   0.05). To rule out the possibility of any nonspecifi  c inter-
feron responses associated with siRNA, a pSUPER construct 
expressing siRNA with a sequence unrelated to IGFBP-5 was 
engineered and introduced to C2C12 cells. This construct did 
not affect differentiation or MHC expression (  Fig. 2, C  –  E  ). 
Together, these results indicated that knockdown of IGFBP-5 
impairs myogenic differentiation in C2C12 cells. 
  Knockdown of IGFBP-5 suppresses 
myogenin expression, but expression 
of Myogenin cannot   “  rescue  ”   the myogenic 
defects caused by IGFBP-5 knockdown 
 The  muscle-specifi  c myogenic regulatory factors, including 
MyoD, Myf5, MRF4, and Myogenin regulate myoblast specifi  -
cation and differentiation through their ability to activate muscle 
specifi  c structural genes, such as MHC (  Perry and Rudnick, 
2000  ). We examined whether the expression of some of these 
critical myogenic transcription factors is altered by IGFBP-5 
knockdown. There was little difference of MyoD levels through 
the time course of differentiation (  Fig. 3 A  ). Myogenin was not 
detectable in undifferentiated myoblast cells or within the fi  rst 
24 h after DM was added (  Fig. 3 B  ). At 48 h, Myogenin was 
increase at 72 h and an additional approximate twofold increase 
at 96 h. RT-PCR analysis indicated that there are no signifi  cant 
changes in the mRNA levels of IGF-IR, IGFBP-2, and IGFBP-4 
(unpublished data; also see Fig. 5 A). These results suggest that 
although both IGF-II and IGFBP-5 expression are induced during 
myogenic differentiation, the induction of IGFBP-5 expression 
precedes that of IGF-II. 
  Induction of IGFBP-5 expression 
is required for myogenic differentiation 
  To determine the role of endogenous IGFBP-5, pSUPER-BP5, 
a plasmid that generates siRNA specifi  cally targeting IGFBP-5 
mRNA, was transfected to cultured C2C12 cells. The effect in 
silencing the IGFBP-5 gene was examined by measuring changes 
in IGFBP-5 mRNA, as well as changes in IGFBP-5 protein levels. 
Introducing pSUPER-BP5 into these cells resulted in a marked re-
duction of IGFBP-5 mRNA levels, whereas the empty pSUPER 
plasmid had no such effect (  Fig. 2 A  ). Ligand blot analysis of 
the conditioned media revealed a similar decrease in IGFBP-5 
protein levels (  Fig. 2 B  ). The specifi  city of IGFBP-5 siRNA was 
confirmed by the unchanged levels of IGFBP-4 mRNA and 
GAPDH mRNA (  Fig. 2 A  ). Quantifi  cation of three independent 
experiments showed that IGFBP-5 siRNA caused a 72.8% de-
crease (P   <   0.05) in IGFBP-5 mRNA levels and a 71.2% de-
crease (P   <   0.05) in protein levels. 
  When switched to DM, the empty control vector  –  trans-
fected myoblasts formed morphologically distinctive multi-
nucleated myotubes, while pSUPER-BP5 – transfected myoblasts 
  Figure 2.       Knockdown of IGFBP-5 impairs myogenic differentiation.   (A) C2C12 cells were transfected with pSUPER or pSUPER-BP5. 3 d later, total RNA 
was isolated and subjected to Northern blot analysis. (B) Conditioned media obtained from wild-type, pSUPER-BP5  –  transfected, and pSUPER-transfected 
cells were subjected to ligand blot analysis. (C) Knockdown of IGFBP-5 inhibits myotube formation. C2C12 cells were transfected with the pSUPER vector 
(a), pSUPER-BP5 (b), or control pSUPER (c). 30 h after transfection, cells were induced to differentiate for 4 d. Images were representative from three re-
producible experiments. Bar, 200   μ  m. (D) Knockdown of IGFBP-5 reduces MHC expression. Cells described in C were analyzed by immunostaining for MHC 
(a, c, and e) and counterstained with DAPI (b, d, and f). Bar, 200   μ  m. (E) Western immunoblot analysis of cells described in C.     JCB • VOLUME 182 • NUMBER 5 • 2008  982 
genin and pSUPER-BP5 were indistinguishable from those trans-
fected with pSUPER-BP5 alone, i.e., they did not form myotubes 
and had minimal MHC expression when grown in DM. To con-
fi  rm that the myogenin transgene is functional in this particular 
experimental setting, the transcriptional activity of Myc-Myo-
genin was examined. Myogenin forms heterodimers with other 
ubiquitous basic helix-loop-helix transcription factors and binds 
to the cis-control elements termed E-boxes often found in the 
promoters of muscle-specifi  c genes ( Sabourin and Rudnicki, 2000 ; 
  Buckingham, 2001  ). 4RTK is a reporter construct that contains 
the fi  refl  y luciferase gene driven by a minimal thymidine kinase 
(TK) promoter linked with four copies of the E-box derived 
from the mouse muscle creatine kinase promoter. As shown in 
  Fig. 4 C  , when cotransfected with 4RTK, the Myc-Myogenin 
caused a sixfold increase in luciferase activity. Furthermore, 
when transfected to C2C12 cells, Myogenin signifi  cantly in-
creased differentiation at 24 and 36 h after the induction of 
differentiation (  Fig. 4 D  ), suggesting that overexpression of 
Myogenin is capable of promoting differentiation. Together, 
these data indicate that while knockdown of IGFBP-5 reduces 
myogenin gene expression, myogenin alone is insuffi  cient to 
promote myogenic differentiation in the absence of IGFBP-5. 
  Knockdown of IGFBP-5 suppresses 
IGF-II gene expression and exogenous IGF-II 
  “  rescues  ”   the myogenic defects caused 
by IGFBP-5 knockdown 
  It has been reported that autocrine IGF-II is a critical regulator 
of myogenesis (  Wilson et al., 2004  ). We therefore examined the 
impact of IGFBP-5 knockdown on IGF-II expression. No IGF-II 
mRNA was detected by RT-PCR in the control undifferentiated 
C2C12 myoblast cells (  Fig. 5 A  ). 24 h after the addition of DM, 
the IGF-II mRNA levels were appreciated and showed further 
increases at 48 h and thereafter. IGF-II mRNA expression was 
undetectable at 24 h and was markedly lower at 48 h in the 
pSUPER-BP5 – transfected cells. This effect appears to be specifi  c 
easily detectable and its levels increased dramatically at 72 and 
96 h in the control group. At 48 and 72 h, Myogenin was not 
detected in pSUPER-BP5  –  transfected cells (  Fig. 3 B  ). Its levels 
were markedly lower even at 96 h. Northern blot analysis re-
vealed similar decreases in myogenin mRNA levels (  Fig. 3 C  ). 
  To determine whether myogenin mediates the myogenic 
action of IGFBP-5, we cotransfected C2C12 myoblasts with 
pSUPER-BP5 and a Myogenin expression plasmid. Western 
blot analysis verifi  ed the successful expression of the Myc-tagged 
Myogenin. Knockdown of IGFBP-5 suppressed the endogenous 
Myogenin and modestly decreased the levels of the transgene 
(  Fig. 4 A  ). As shown in   Fig. 4 B  , cells cotransfected with Myo-
  Figure 3.       Knockdown of IGFBP-5 decreases Myogenin expression.   After 
transfection, C2C12 myoblasts were switched to DM. Samples were col-
lected at the indicated time. (A) Western immunoblot of MyoD. (B) Western 
immunoblot analysis of Myogenin. (C) Northern blot analysis of myogenin.     
  Figure 4.       Forced expression of Myogenin does not 
rescue the myogenic defects in IGFBP-5  –  deﬁ  cient cells.   
(A) Western immunoblot analysis of C2C12 cells transfected 
with pSUPER + pCS2, pSUPER-BP5 + pCS2, pSUPER + 
Myc-tagged Myogenin, or pSUPER-BP5 + Myc-tagged 
Myogenin 4 d after they were induced to differentiate. 
(B) Phase-contrast images of cells transfected with pSUPER 
+ pCS2 (a), pSUPER-BP5 + pCS2 (b), pSUPER + Myc-
tagged Myogenin (c), and pSUPER-BP5 + Myc-tagged (d). 
These were representative images from four reproducible 
experiments. Bar, 200   μ  m. (C) Luciferase activity was 
measured 2 d after differentiation was induced in C2C12 
cells transfected with an empty vector and the Myogenin 
reporter construct 4RTK, Myc-tagged Myogenin and the 
reporter construct TK, and overexpression of Myogenin 
and 4RTK, respectively. Data are expressed as relative 
value to those of the empty vector and 4RTK transfected 
cells. Data shown are means   ±   SE of three independent 
experiments. *, P   <   0.05. (D) C2C12 cells were trans-
fected with either EGFP or EGFP-tagged Myogenin and 
induced to differentiate for 24 or 36 h, and their differentia-
tion indexes were determined. Data shown are means   ±   SE 
of two independent experiments each performed in triplicate. 
*, P   <   0.05.     983 IGFBP-5 PROMOTES THE MYOGENIC ACTION OF IGF-II   • Ren et al. 
phospho-Akt/total Akt, the levels in the IGFBP-5 – defi  cient group 
showed a 94% reduction (  Fig. 5 C  ). 
  Because knockdown of IGFBP-5 suppresses IGF-II ex-
pression and reduces the IGF signaling activity, we tested whether 
IGFBP-5 affects myogenesis via IGF-II. As shown in   Fig. 6 A  , 
while pSUPER-BP-5 transfected cells remained as mononucle-
ated myoblasts, addition of exogenous IGF-II not only increased 
myotube formation in the control group, it also reversed the 
myogenic defects caused by IGFBP-5 knockdown. IGF-I, which 
signals through the same IGF-IR, had a similar effect. Western blot 
to the IGF-II gene, as knockdown of IGFBP-5 did not reduce 
the mRNA levels of other members of the IGF signaling path-
way expressed in these cells, including IGF-I, IGF-IR, and 
IGFBP-2 and -4 (  Fig. 5 A  ). The effect on IGF-II gene expres-
sion was further examined by qRT-PCR. IGF-II mRNA levels 
were signifi  cantly lower in IGFBP-5 knocked down cells at 24, 
48, and 72 h after the induction of differentiation (  Fig. 5 B  ). 
Knockdown of IGFBP-5 markedly decreased phospho-Akt lev-
els, whereas the levels of total Akt remained comparable to those 
of the control. When quantifi  ed and expressed as the ratio of 
  Figure 5.       Knockdown of IGFBP-5 suppresses IGF-II gene 
expression and decreases IGF-IR  –  mediated signaling 
activity.   (A) C2C12 cells transfected with pSUPER or 
pSUPER-BP5 were induced to differentiate by switching to 
DM. RNA samples were prepared at the indicated time 
points and subjected to RT-PCR. (B) RNA samples described 
in A were analyzed by qRT-PCR. Data are expressed as 
relative value to those of the pSUPER transfected cells at 
24 h after the induction of differentiation. Data shown 
are means   ±   SE of three independent experiments. *, P   <   
0.05; **, P   <   0.01; ***, P   <   0.001 compared with the 
pSUPER-transfected control groups at the same time point. 
(C) Cells transfected with pSUPER or pSUPER-BP5 was in-
duced to differentiate. 48 h later, cells were lysed and 
analyzed by Western immunoblot. The phospho-Akt/total 
Akt ratio was calculated by densitometry. Values are ex-
pressed as relative levels to pSUPER group. Data shown 
are means   ±   SE;   n   = 4; *, P   <   0.05.     JCB • VOLUME 182 • NUMBER 5 • 2008  984 
  If IGFBP-5 indeed promotes myogenesis through the IGF-
IR-PI3K-Akt signaling pathway, then activation of Akt should 
also   “ rescue ”   IGFBP-5  knockdown-induced  differentiation  de-
fects. To test this idea, myrAkt, a constitutively active form of 
Akt, was introduced to the cells. As shown in   Fig. 6 D  , C2C12 
cells cotransfected with pSUPER-BP5 and a myrAkt-expressing 
analysis indicated that knockdown of IGFBP-5 suppressed MHC 
and Myogenin expression and addition of IGF-II restored their 
expression (  Fig. 6 B  ). This action of exogenous IGF-II is likely 
mediated by the IGF-IR and Akt signaling pathway because 
knockdown of IGFBP-5 reduced phospho-Akt levels and IGF-II 
increased phospho-Akt levels in differentiating cells (  Fig. 6 C  ). 
  Figure 6.       Exogenous IGFs or expression of a constitutively 
active Akt   “  rescues  ”   the myogenic defects caused by IGFBP-5 
knockdown.   (A) Effects of IGFs. C2C12 cells transfected with 
pSUPER (a, c, and e) or pSUPER-BP5 (b, d, and f) were in-
duced to differentiate by switching to the DM containing 
0.5% horse serum without IGF-I (a and b), or with 400 ng/ml 
IGF-I (c and d), or 400 ng/ml IGF-II (e and f) for 4 d. Rep-
resentative images from four reproducible experiments are 
shown. Bar, 200   μ  m. (B) Western immunoblot analysis of cell 
lysates from the groups indicated. (C) Western immunoblot 
analysis of Akt in cell lysates from the groups indicated. 
(D) Effect of myrAkt. C2C12 cells transfected with pSUPER + 
pCS2 (a), pSUPER-BP5 + pCS2 (b), pSUPER + pCS2+myr-Akt 
(c), and pSUPER-BP5 + pCS2+myr-Akt (d) were switched to 
the DM containing 0.5% horse serum for 4 d. Phase-contrast 
images were representative images from two independent 
experiments. Bar, 200   μ  m. (E) Western immunoblot analysis 
of cell lysates from the groups indicated.     
  Figure 7.       IGF-II up-regulates its own gene ex-
pression through the PI3K-Akt signaling pathway.   
(A) Wild-type C2C12 cells were switched to SFM 
supplemented with or without 300 ng/ml IGF-II. 
IGF-II mRNA levels were measured by qRT-PCR 
and normalized by cyclophilin mRNA levels. Data 
shown represent means   ±   SE of two independent 
experiments. *, P   <   0.05 compared with the con-
trol group at the same time point. (B) Wild-type 
C2C12 cells were switched to DM (containing 
0.5% horse serum) supplemented with or without 
300 ng/ml IGF-II. 24 and 36 h later, cells were 
lysed and subjected to Western blot analysis. 
(C) Cells transfected with the empty pCS2 (open 
box) or pCS2+myr-Akt plasmid (closed box) were 
switched to DM. IGF-II mRNA levels were mea-
sured by qRT-PCR and normalized. The results 
were expressed as relative value to those of the 
empty vector transfected cells at 0 h. Data shown 
are means   ±   SE of three independent experiments. 
*, P   <   0.05; **, P   <   0.01 compared with the con-
trol group at the same time point. (D) C2C12 cells 
transfected with the empty pCS2+ or pCS2+myr-
Akt plasmid were switched to the DM. Cells were 
lysed at the indicated time and subjected to West-
ern blot analysis. (E) Overexpression of Myogenin 
does not restore the reduced IGF-II expression in 
IGFBP-5 knocked down cells. Cells transfected 
with pSUPER + pCS2, pSUPER + Myc-Myogenin, 
pSUPER-BP5 + pCS2, and pSUPER-BP5 + Myc-
Myogenin were induced to differentiate for 4 d. 
RNA samples were prepared and subjected to 
RT-PCR analysis.     985 IGFBP-5 PROMOTES THE MYOGENIC ACTION OF IGF-II   • Ren et al. 
DAPI signal (  Fig. 8 A  , e – h).  These  results  indicate endogenous 
IGFBP-5 is not localized in the nucleus in myoblasts. Next, we 
transfected C2C12 cells with an IGFBP-5 construct that contains 
its functional transactivation domain (  Xu et al., 2004  ) and ex-
amined its impact on the IGF-II gene expression. As shown in 
  Fig. 8 B  , no signifi  cant increase was detected in IGF-II mRNA ex-
pression levels in the control or IGFBP-5 transfected cells, although 
the IGFBP-5 fusion protein was highly expressed (  Fig. 8 C  ). 
In comparison, myrAkt overexpression signifi  cantly increased 
IGF-II mRNA levels (  Fig. 8 B  ). Together, these results suggest 
that endogenous IGFBP-5 is not localized in the nucleus and 
forced nuclear expression of the IGFBP-5 transactivation do-
main does not increase IGF-II expression in differentiating 
myoblast cells. 
  IGFBP-5 promotes myogenic differentiation 
by switching on the IGF-II auto-regulation 
loop 
  How does IGFBP-5 act to increase IGF-II gene expression and 
to promote myogenesis? IGFBP-5 has been shown to be located 
on the cell surface and/or extracellular matrix in fi  broblasts and 
muscle cells (  Clemmons, 2001  ). Because IGF-II stimulates its 
own gene expression through a positive auto-regulatory loop, we 
hypothesized that cell surface  –  associated IGFBP-5 up-regulates 
IGF-II gene expression and promotes myogenesis by binding 
to IGF-II and enhances its interaction with the IGF-IR, thereafter 
plasmid clearly formed myotubes when growing in DM, whereas 
cells transfected with pSUPER-BP5 did not. Cells transfected 
with the myrAkt plasmid alone showed enhanced differentiation. 
Similarly, expression of myrAkt restored pSUPER-BP5 caused 
reduction in Myogenin and MHC expression ( Fig. 6 E ). Together, 
these fi  ndings suggest that knockdown of IGFBP-5 suppresses 
IGF-II expression, which in turn leads to reduced signaling inten-
sity of the IGF-IR-PI3K-Akt signaling pathway. 
  IGF-II up-regulates its own gene expression 
via the PI3K-Akt signaling pathway 
  Although it has been shown that autocrine IGF-II production in-
creases dramatically during muscle differentiation, the regulatory 
mechanisms of IGF-II gene expression is not well understood. 
Given the fact that IGF-II gene expression is continuously and 
dramatically elevated during myogenesis (see   Fig. 1  ), we specu-
lated that IGF-II might up-regulate its own gene expression through 
a positive auto-regulatory loop. Two independent approaches, 
adding exogenous IGF-II and overexpressing myrAkt, were taken 
to address this issue. As shown in   Fig. 7 A  , addition of IGF-II to 
wild-type C2C12 cells resulted in a signifi  cant increase in IGF-II 
mRNA levels. Likewise, expression of myrAkt signifi  cantly in-
creased IGF-II mRNA levels (  Fig. 7 C  ). These results suggest that 
IGF-II up-regulates its own gene expression through the PI3K 
and Akt signaling pathway. 
  In addition to IGF-II, Myogenin expression was also 
increased by exogenous IGF-II or myrAkt expression (  Fig. 7, 
B and D  ). These data are consistent with previous reports (  Florini 
et al., 1993  ;   Xu and Wu, 2000  ). However, expression of Myogenin 
did not restore the reduced IGF-II expression caused by IGFBP-5 
knockdown cells (  Fig. 7 E  ). Although the increased Myogenin 
plays a role in myogenesis, it does not appear to play any direct 
role in the expression of the IGF-II gene during myogenesis. 
  Endogenous IGFBP-5 is not localized in the 
nucleus, and forced nuclear expression 
of the IGFBP-5 transactivation domain 
does not increase IGF-II expression 
  Recent studies have shown that IGFBP-5 is not only secreted, 
but can also enter the nucleus in certain cell types and that IGFBP-5 
contains a functional transactivation domain in its conserved 
N-domain (  Firth and Baxter, 2002  ;   Xu et al., 2004  ;   Zhao et al., 
2006  ). We wondered whether IGFBP-5 could exert a direct effect 
on IGF-II transcription in the nucleus. To test this idea, immuno-
cytochemical experiments were performed to determine whether 
endogenous IGFBP-5 is present in the nucleus in differentiating 
C2C12 cells. Confocal microscopy analysis showed that endog-
enous IGFBP-5 signal was detected in the Golgi apparatus, in 
the shape of a crescent moon outside of the nucleus (  Fig. 8 A  , 
a  –  d). This is consistent with the fact that IGFBP-5 is secreted 
from these cells. To show that the IGFBP-5 antibody could de-
tect nuclear IGFBP-5 if present, we generated a plasmid that ex-
presses a nonsecreted form of IGFBP-5 (with the signal peptide 
deleted) with an EGFP tag at its N terminus, and introduced it 
into cells by transient transfection. The nonsecreted EGFP-
mIGFBP-5 was clearly localized in the nucleus as indicated by 
the overlap of GFP signal and IGFBP-5 immunoreactivity with 
  Figure 8.       IGFBP-5 does not exert direct effect on IGF-II gene expression.   
(A) IGFBP-5 is not localized in the nucleus. C2C12 cells were transfected 
with either pcDNA3.1-EGFP (a  –  d) or pcDNA3.1-EGFP-mIGFBP-5 (e  –  h). 
24 h after the induction of differentiation, cells were ﬁ  xed, the membrane 
permeabilized, and stained with an IGFBP-5 antibody (b and f) and coun-
ter-stained with DAPI (c and g). Panels a and e are GFP signal, and pan-
els d and h are overlays. Bar, 10   μ  m. (B) Forced nuclear expression of 
the IGFBP-5 transactivation domain does not increase IGF-II expression. 
C2C12 cells were transfected with either pBIND vector, pBIND-BP5, or 
myrAkt and induced to differentiate. 36 h later, total RNA samples were 
isolated and IGF-II mRNA levels were determined by qRT-PCR. Values are 
relative to the control group after normalized by cyclophilin levels. *, P   <   
0.05 compared with the control group. (C) Western blot of cell lysates 
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ing differentiation. Because IGFBP-5 is the predominant IGFBP 
secreted by these cells, the reduced activity of Des(1-6)IGF-II is 
consistent with the notion that endogenous IGFBP-5 binds to 
IGF-II and promotes IGF-II actions. To test this further and to 
determine whether the potentiation effect of IGFBP-5 is indeed 
due to its binding to IGF-II, IGF-II and IGFBP-5 were added 
individually or in combination to cells transfected with pSUPER 
or pSUPER-BP5. pSUPER-BP5  –  transfected cells did not form 
myotubes and had signifi  cantly reduced MHC levels (  Fig. 9 D  ). 
Addition of a relatively high concentration (150 ng/ml) of IGF-II 
partially   “  rescued  ”   these myogenic defects caused by IGFBP-5 
knockdown. At a low concentration (50 ng/ml), however, IGF-II 
by itself had little effect. When the low concentration of IGF-II 
(50 ng/ml) was added in combination with an equal molar con-
centration of IGFBP-5 (210 ng/ml) to pSUPER-BP5  –  transfected 
cells, these cells showed comparable degree of myotube forma-
tion and MHC expression to those of the high IGF-II (150 ng/ml) 
group and the control pSUPER group. IGFBP-5 (210 ng/ml) 
alone had no rescuing effect (  Fig. 9 D  ). These results suggest 
that IGFBP-5 does not act directly to affect myogenic differen-
tiation. Rather, it works primarily by potentiating or amplifying 
IGF-II actions. 
  Next, LBD-IGFBP-5, an IGFBP-5 mutant with amino 
acid substations in the ligand binding domain and having 800-
fold lower affi  nity to IGFs (  Imai et al., 2000  ), was used to examine 
the mechanistic basis of IGFBP-5 action. As shown in   Fig. 9 D  , 
when added together with IGF-II (50 ng/ml) to pSUPER-BP5  –
  transfected cells, IGFBP-5-LBD did not increase myotube 
formation or MHC expression, suggesting that the action of 
IGFBP-5 in promoting myogenic differentiation is dependent 
on its ability to bind to IGF-II. 
  The IGFBP-5 and IGF-II genes are 
similarly induced in primary myoblasts 
and IGFBP-5 knockdown inhibits primary 
cell differentiation 
  To establish the physiological relevance of the above observa-
tions, we examined the IGF-II and IGFBP-5 mRNA expression 
patterns in primary skeletal myoblasts prepared from neonatal 
mice. As shown in   Fig. 10 A  , 24 h after the initiation of differ-
entiation, the expression of IGFBP-5 mRNA showed a 2.9-fold 
increase over the 12 h control (P  <  0.05). Thereafter, the IGFBP-5 
mRNA levels returned to the basal levels. In comparison, the 
IGF-II mRNA level remained unchanged at this early stage of 
differentiation. The IGF-II mRNA levels increased signifi  cantly 
at 36 h (4.6-fold over 12 h, P   <   0.05) and remained signifi  cantly 
high at 48 h (3.6-fold, P   <   0.05). Therefore, the overall patterns 
of IGF-II and IGFBP-5 induction and their temporal relation-
ship are similar in these primary cells, although the magnitude 
of inductions is lower. To examine the role of IGFBP-5, pri-
mary skeletal muscle cells were transfected with pSUPER or 
pSUPER-BP5. When switched to DM, the vector transfected 
myoblasts formed morphologically distinctive multinucleated 
myotubes and expressed MHC (  Fig. 10 B  ). In comparison, most 
pSUPER-BP5  –  transfected myoblasts had fewer MHC-positive 
cells. The differentiation index in the pSUPER-BP5 – transfected 
group is 37.5% (  Fig. 10 C  ), which is signifi  cantly lower than 
amplifying IGF signaling activity during myogenesis. To test this 
hypothesis, immunocytochemical staining was performed. As 
shown in   Fig. 9 A  , IGFBP-5 signal was clearly observed on 
the surface of cells that were fi  xed in a buffer containing no de-
tergent and therefore with the integrity of the plasma membrane 
intact (panel a). When the plasma membrane was permealized, 
however, no such signal was observed, even though intracellular 
IGFBP-5 was clearly visible (  Fig. 9 A  , panel b). We further dem-
onstrated that intact IGFBP-5 is present on the surface of differ-
entiating myoblasts and is capable of IGF binding by treating 
C2C12 cells with a high salt buffer to release its cell surface  –
  bound IGFBP-5. As shown in   Fig. 9 B  , no cell surface  –  associated 
IGFBP-5 was found in myoblasts before the induction of dif-
ferentiation. In contrast, a large amount of intact IGFBP-5 was 
detected on the surface of these cells 24 h after the induction 
of differentiation. 
  Next, we compared the myogenic activities of IGF-II 
or Des(1-6)IGF-II. Des(1-6)IGF-II binds to the IGF-IR but 
does not bind to IGFBPs. As shown in   Fig. 9 C  , compared with 
IGF-II, Des(1-6)IGF-II was signifi  cantly less potent in stimulat-
  Figure 9.       IGFBP-5 is localized on the cell surface and promotes myogenic 
differentiation by binding to and promoting IGF-II action.   (A) 24 h after 
the induction of differentiation, C2C12 cells were ﬁ  xed without (a) or with 
(b) membrane permeabilization and stained with an IGFBP-5 antibody. 
Bar, 10   μ  m. (B) 0 and 24 h after induction of differentiation, C2C12 cells 
were incubated with a high salt buffer to strip off membrane/ECM bound 
IGFBP-5. The released IGFBP-5 was detected by ligand blot. (C) C2C12 
cells were switched to serum-free medium containing 300 ng/ml IGF-II or 
Des(1-6)IGF-II. 36 h later, the cells were subjected to MHC immunostaining 
and DAPI staining and the differentiation index determined as described 
in Materials and methods. Data are means   ±   SE of three independent 
experiments with duplicates. Group *, #, and      are signiﬁ  cantly differ-
ent from each other at P   <   0.05. (D) Cells transfected with pSUPER or 
pSUPER-BP5 were switched to DM (containing 0.5% horse serum) without 
or with 50 ng/ml IGF-II, 50 ng/ml IGF-II + 210 ng/ml wild  –  type IGFBP-5, 
210 ng/ml wild-type IGFBP-5, 50 ng/ml IGF-II + 210 ng/ml LBD-IGFBP-5, 
210 ng/ml LBD-IGFBP-5, or 150 ng/ml IGF-II for 4 d. MHC levels were 
measured by Western immunoblot and quantiﬁ  ed by densitometry. Values 
are expressed as relative to the IGFBP-5 siRNA group. Data are means   ±   
SE of 3  –  4 independent experiments. Group * is signiﬁ  cantly different from 
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differentiation-promoting factor in skeletal muscle cells. This con-
clusion makes physiological sense in light of the highly induced 
IGFBP-5 expression before an appreciable increase in IGF-II 
production during early myogenesis. It is also in agreement with 
several previous studies. It has been reported that NFB4 cells, a 
mutant muscle cell line derived from C2C12 cells that are defi  -
cient in IGFBP-5 and IGF-II, do not undergo differentiation un-
der the conditions in which C2C12 cells differentiate ( Sarbassov 
et al., 1995  ). When added in an appropriate ratio to IGF-I, 
IGFBP-5 stimulates IGF-induced myoblast differentiation in rat 
muscle cells (  Ewton et al., 1998  ). Recent loss-of-function stud-
ies in other cell types also suggest that IGFBP-5 promote bone, 
neuronal and epithelial cell differentiation ( Yin et al., 2004 ;  Tanno 
et al., 2005 ;  Kiepe et al., 2006 ;  Lochrie et al., 2006 ). More impor-
tantly, the IGFBP-5 and IGF-II genes exhibit similar expression 
that of the control group (58.4%, P   <   0.05). These fi  ndings sug-
gest that the induction of IGFBP-5 occurs earlier than that of 
IGF-II and that IGFBP-5 promotes myogenic differentiation in 
primary skeletal muscle cells. 
  Discussion 
  In this study, we have explored the role(s) of endogenous 
IGFBP-5 in modulating the action of autocrine IGF-II in pro-
moting myogenic differentiation. We show that knockdown of 
IGFBP-5 impairs myogenic differentiation. Addition of IGF-II 
 “ rescues ”  IGFBP-5 knockdown-induced myogenic defects, while 
Des(1-6)IGF-II, an IGF-II analogue with greatly reduced bind-
ing affi  nity for IGFBP, is signifi  cantly less effective. These data 
strongly argue that the endogenously secreted IGFBP-5 is a 
  Figure 10.       The IGF-II and IGFBP-5 genes exhibit similar induction patterns and IGFBP-5 knockdown inhibits myogenic differentiation in primary skeletal 
muscle cells.   (A) Total RNA was extracted from primary mouse skeletal myoblasts at the time indicated after the induction of differentiation. IGF-II mRNA 
and IGFBP-5 mRNA levels were measured by qRT-PCR. Values are expressed as relative levels to that of 12 h. Data shown are means   ±   SE of three in-
dependent experiments each performed in duplicate. Groups labeled with different symbols are different from each other at P   <   0.05. (B) Neonatal mouse 
myoblasts were transfected with the empty pSUPER vector (a) or pSUPER-BP5 (b). 30 h after transfection, cells were induced to differentiate. Representative 
images from two independent groups are shown. Bar, 200   μ  m. (C) Quantiﬁ  ed results of B. (D) A proposed model on how IGFBP-5 and IGF-II act in concert 
to stimulate myogenic differentiation. IGFBP-5 is induced in early stages of myogenesis and is located on the cell surface. Cell surface  –  associated IGFBP-5 
binds to IGF-II and targets IGF-II to the close proximity of the IGF-IR receptor, thereby enhancing IGF-IR  –  mediated signaling activity, leading to a further 
increase in IGF-II gene expression. This, in turn, results in an accelerated increase in the IGF-IR-PI3K-Akt signaling activity, leading to increases in Myogenin 
expression, and promoting myogenic differentiation.     JCB • VOLUME 182 • NUMBER 5 • 2008  988 
suppressed IGF-II expression was reversed by adding IGFBP-5 
together with low concentrations of IGF-II or by a high con-
centration of IGF-II. Expression of myrAkt also restores IGF-II 
expression levels. We also ruled out nonspecifi  c interferon re-
sponses using another pSUPER construct expressing siRNA 
with a sequence unrelated to IGFBP-5. Our data showed that 
myrAkt overexpression signifi  cantly increased IGF-II gene ex-
pression 12 h after differentiation was induced. It is possible 
that Akt also regulates IGF-II gene expression during the early 
phase of myogenesis.   Erbay et al. (2003)   showed that mTOR 
signaling, which is downstream of Akt, is important for IGF-II 
induction during early phase of myogenic differentiation (3 h after 
differentiation was induced). However, further studies are needed 
to further clarify this issue. 
  IGFBP-5 is not only secreted but can also enter the nu-
cleus in certain cell type (  Firth and Baxter, 2002  ). We have re-
cently reported that IGFBP-5 contains a functional transactivation 
domain in its conserved N-domain and this activity is IGF-binding 
independent (  Xu et al., 2004  ;   Zhao et al., 2006  ). Furthermore, 
full-length IGFBP-5 has transcriptional repressing activity (  Zhao 
et al., 2006  ). Our fi  nding that IGFBP-5 knockdown suppresses 
IGF-II mRNA expression in differentiating muscle cells raised 
the possibility that IGFBP-5 may exert direct an effect on IGF-II 
gene transcription in the nucleus. Two approaches were taken to 
address this intriguing hypothesis. First, immunocytochemical 
staining experiments showed that endogenous IGFBP-5 protein 
was detected in the Golgi apparatus and on the cell surface but not 
in the nuclei in myoblasts. Second, expression of the IGFBP-5 
transactivation domain did not cause any signifi  cant change in 
IGF-II mRNA expression levels. These results argue against a 
direct action of IGFBP-5 on the IGF-II gene transcription in this 
cell type. 
  It is of interest to fi  nd that IGF-II up-regulates its own 
gene expression in differentiating C2C12 myoblasts. Although 
previous studies have indicated that nutrients infl  uence IGF-II 
gene expression in C2C12 cells through the PI3K-Akt-mTOR 
pathway (  Erbay et al., 2003  ), to our knowledge, this is the fi  rst 
demonstration that IGF-II stimulates its own gene expression in 
skeletal muscle cells. Furthermore, forced expression of a con-
stitutive Akt strongly increases IGF-II expression in these cells, 
suggesting that IGF-II auto-regulates itself through activating 
the IGF-IR-PI3K-Akt signaling pathway in C2C12 cells. This 
and other fi  ndings led us to propose a new model, depicted in 
  Fig. 10 D  , on how IGFBP-5 acts to promote myogenic differen-
tiation. According to this model, the induction of IGFBP-5 in 
early stages of myogenic differentiation plays a crucial role in 
promoting the myogenic action of autocrine IGF-II. IGFBP-5 
acts by binding to IGF-II and promoting its interaction with 
IGF-IR. This interaction may contribute to reaching a certain 
threshold that turns on the IGF-II positive auto-regulatory loop, 
thereby resulting in increased IGF-II gene expression. The in-
crease in IGF-II production, in turn, results in an accelerated el-
evation in the IGF-IR-PI3K-Akt signaling activity, leading to 
increases in Myogenin, MHC expression, and myotube forma-
tion. This model is supported by several lines of evidence. First, 
IGFBP-5 is induced in early stages of myogenesis, before the 
elevation of IGF-II expression, in the C2C12 myoblast model 
patterns in primary skeletal muscle cells and knockdown of 
IGFBP-5 inhibits myogenic differentiation in primary cells. These 
fi  ndings suggest that IGFBP-5 promotes muscle cell differentia-
tion and this fi  nding is of physiological relevance. 
 Our  fi  nding, however, contradicts the view that IGFBP-5 
is a negative factor of myogenesis. Several previous studies in 
C2 myoblasts have shown that stably overexpressing IGFBP-5 
under a constitutive promoter impairs myogenic differentiation, 
presumably by binding to and sequestering IGF-II from its bind-
ing to the IGF-IR (  James et al., 1996  ;   Mukherjee et al., 2007  ). 
The different fi  ndings on the precise role IGFBP-5 in myogenesis 
could be due to different experimental approaches used. In the 
present study, we explored the role of endogenous IGFBP-5 
through a loss-of-function approach followed by   “  rescuing  ”   us-
ing proteins, whereas previous studies primarily relied on over-
expression approaches. The different results may also be due to 
different cell lines used. Previous studies were conducted ex-
periments with C2 cells (  James et al., 1996  ;   Cobb et al., 2004  ; 
  Mukherjee et al., 2007  ). Instead, we used the C2C12 cell line, 
which is subcloned from the parent C2 cell line by selection for 
the ability to differentiate rapidly and produce extensive con-
tracting myotubes (  Silberstein et al., 1986  ). Moreover, we ob-
tained similar results in primary skeletal muscle cells, strongly 
supporting the physiological relevance of our fi  ndings. 
  IGFBP-5, Myogenin, and IGF-II are all induced during 
differentiation (  Rotwein et al., 1995  ;   Bayol et al., 2000  ). The ex-
pression of IGFBP-5 correlates well with the expression of Myo-
genin (  Bergstrom and Tapscott, 2001  ). Myogenin, IGF-II, and 
IGFBP-5 were undetectable in the mutant NFB4 cells, which 
cannot go through differentiation (  Sarbassov et al., 1995  ). In 
cultured muscle cells, endogenously secreted IGF-II stimulates 
the IGF-IR, PI3K, and Akt to induce the expression of Myo-
genin (  Wilson et al., 2004  ). The functional relationship between 
IGFBP-5, Myogenin, and IGF-II is not well understood. In this 
study, we found that IGFBP-5 knockdown caused marked re-
duction in both Myogenin and IGF-II expression, but had little 
effect on MyoD expression. Forced expression of functional 
Myogenin, however, failed to rescue the differentiation defects 
caused by IGFBP-5 knockdown, although it increased the dif-
ferentiation index in the wild-type cells. It is noted that IGFBP-5 
siRNA not only markedly decreased endogenous Myogenin ex-
pression levels but also caused a modest reduction in the ex-
pression levels of the Myogenin transgene. Importantly, forced 
expression of Myogenin did not cause signifi  cant changes in ei-
ther IGF-II or IGFBP-5 mRNA levels. This suggests that while 
IGF-II and IGFBP-5 regulates Myogenin expression, Myogenin 
itself is not suffi  cient to induce myogenic differentiation in the 
absence of IGFBP-5 and/or IGF-II. Other factors must also be 
involved in the effect of IGFBP-5 on myogenesis. Future stud-
ies are needed to identify these factors. 
  One of the intriguing fi  ndings made in this study is that 
IGFBP-5 knockdown suppresses IGF-II expression. IGFBP-5 
knockdown had little effect on the IGF-I and IGF-IR mRNA 
levels. Knockdown of IGFBP-5 did not affect the levels of other 
IGFBPs synthesized by C2C12 either. The specifi  city of this 
siRNA construct has been verifi  ed using a siRNA resistant form 
of IGFBP-5 in U2OS cells (  Yin et al., 2004  ). In addition, the 989 IGFBP-5 PROMOTES THE MYOGENIC ACTION OF IGF-II   • Ren et al. 
Rad Laboratories. All other chemicals were reagent grade and were pur-
chased from Thermo Fisher Scientiﬁ  c unless otherwise noted. Mice (strains 
CD1) were obtained from Charles River Laboratories. 
  Plasmid construction 
  pSUPER Vector was provided by Dr. Reuven Agami (Netherlands Cancer 
Institute). The construction and veriﬁ  cation of pSUPER-BP-5, which gener-
ates IGFBP-5 siRNA, was described previously (  Yin et al., 2004  ). A control 
pSUPER construct expressing siRNA with a sequence (TCCTGCAGTGGAT-
GGATGT, targeting the mouse TSC2 N-terminal sequence) unrelated to 
IGFBP-5 was also used as a control. Mouse IGF-II cDNA and partial mouse 
IGFBP-5 cDNA were ampliﬁ  ed by RT-PCR and cloned into the pGEM-T easy 
vector (Promega). Myogenin plasmids (pCS2MTMyogenin and pCS2EGFP) 
and the Myogenin reporter construct 4RTK and control TK reporter con-
struct (  Tang et al., 2004  ) were provided by Dr. Daniel Goldman (University 
of Michigan). MyoD cDNA was a gift from Dr. Lassar Andrew (Harvard 
Medical School). The pCS2+myr-Akt construct, which expresses a constitu-
tively active, membrane-localized full-length mouse Akt1 (  Kohn et al., 1998  ), 
was provided by Dr. Anne Vojtek (University of Michigan). The pcDNA3.1 
EGFP-mIGFBP5, which expresses a nonsecreted form of IGFBP-5 with EGFP 
tagged at its N terminus, was generated by inserting mature IGFBP-5 (with 
signal peptide deleted) into the pcDNA3.1(+) vector. All of the plasmids 
were veriﬁ  ed by DNA sequencing. 
  Cell culture and transfection 
  Mouse C2C12 cells were purchased from American Type Culture Collec-
tion (Manassas, VA) and cultured in DMEM supplemented with 10% FBS in 
a humidiﬁ  ed air atmosphere containing 5% CO  2  . For transfection, 6   ×   10 
4   
cells were seeded in 6-well plates (Falcon). 2   μ  g of pSUPER-BP5 or pSUPER 
plasmid DNA was transfected into cells as previously reported (  Yin et al., 
2004  ). 30 h after transfection, the cells were washed and incubated with 
fresh serum-free medium (SFM) for 48 h. At the end of incubation, the con-
ditioned media and total RNA were prepared for further analysis. 30 h 
after transfection, the cells were washed with SFM and then transferred 
to differentiation medium (DM) consisting of DMEM plus 0.5  –  2% horse 
serum. For rescue experiments, 30 h after transfection, the cells were switched 
to DM plus IGF-I, IGF-II, and/or IGFBP-5 with concentration designated in 
each experiment. Primary mouse skeletal myoblasts were isolated from 
2  –  5-d-old mice, grown, and differentiated following a previously reported 
method (  Tang and Goldman, 2006  ). In brief, the forelimbs and hindlimbs 
were removed from neonatal mice. Muscle mass was minced into a coarse 
slurry and enzymatically dissociated at 37  °  C for 35  –  45 min with frequent 
trituration. Isolated muscle cells were grown in DMEM supplemented with 
10% FBS and 10% HS on collagen-coated plates at a density of 2  –  4   ×   10 
5   
cells per 35-mm culture dish. FuGene6 (Roche) was used for transfection of 
these primary cells. Differentiation was induced by switching to DMEM 
medium containing 5% or 1% HS. All experiments were conducted in 
accordance with guidelines approved by the University Committee on the 
Use and Care of Animals (University of Michigan). 
  Northern blot 
  Total RNA was extracted using TriPure Reagent following the manufactur-
er  ’  s instructions. RNA samples were size-fractionated in 1.2% agarose 
gels, blotted, and ﬁ  xed onto Hybond N membranes (GE Healthcare). 
Hybridization was performed using  
32  P-dCTP-labeled (MP Biomedicals) 
IGFBP-5 or IGFBP-4 cDNA probes as reported previously (  Duan et al., 1996  ). 
Labeled GAPDH cDNA was used as a control. The band densities were 
quantiﬁ  ed using Quantity One quantiﬁ  cation software (Bio-Rad Laboratories). 
  Reverse transcription (RT)-PCR and quantitative real-time RT-PCR (qRT-PCR) 
  After treated with DNase, RNA samples were subjected to reverse-tran-
scription using SuperScript II reverse transcription (Invitrogen). Gene spe-
ciﬁ   c primers for IGF-I, IGF-I receptor, IGFBP-2, IGFBP-4, and S17 were 
described previously (  Wilson et al., 2003  ;   Boutinaud et al., 2004  ). IGF-II 
primers for RT-PCR are 5    -GGCTTCTACTTCAGCAGGC-3     (sense), 5    -GGT-
GGTAACACGATCAGGG-3     (antisense). The linear range of product am-
pliﬁ  cation was established in pilot studies for each primer pair. 
  qRT-PCR was performed using an iCycler iQ Multicolor real-time 
PCR detection system (Bio-Rad Laboratories). Primer sequences for qRT-PCR 
were reported by others (  Boutinaud et al., 2004  ). 4   μ  l of the cDNA product 
(1:20 dilution) was used as a PCR template. Plasmid cDNA for cyclophilin 
(  Hasel and Sutcliffe, 1990  ), a housekeeping gene, was provided by 
Dr. Gregor Sutcliffe (Scripps Research Institute). Serial dilutions of the plas-
mids ranging from 10 
8   to 10 molecules/2   μ  l were used for standard curve. 
The number of molecules of particular gene transcript was calculated based 
on the standard curve and normalized to the cyclophilin mRNA level. 
and in primary cells. Second, knockdown of IGFBP-5 im-
pairs myogenic differentiation. Third, knockdown of IGFBP-5 
suppresses IGF-II gene expression and addition of exogenous 
IGF-II   “  rescues  ”   IGFBP-5 knockdown-induced myogenic defects. 
Furthermore, we show that IGF-II up-regulates its own gene 
expression via the PI3K-Akt signaling pathway. Addition of na-
tive IGFBP-5 but not a ligand binding IGFBP-5 mutant, together 
with a low concentration of IGF-II, restores IGF-II expression 
and myogenic differentiation. 
  Although it is known that IGFBP-5 has IGF-independent 
actions (  Clemmons, 2001  ;   Duan, 2002  ;   Firth and Baxter, 2002  ), 
the myogenic promotion action of IGFBP-5 is clearly IGF-
dependent because: (1) immunocytochemistry revealed that endog-
enous IGFBP-5 is not localized to the nuclei of C2C12 cells; 
(2) adding high concentrations of exogenous IGF-I or IGF-II 
reversed IGFBP-5 knockdown caused myogenic defects; (3) 
Des(1-6)IGF-II has lower activity in regulating differentiation; 
and (4) adding native IGFBP-5, but not the LBD mutant IGFBP-5, 
rescued the myogenic defects in the presence of low concentra-
tions of IGF-II. It has been shown that IGFBP-5 is not only present 
in the extracellular fl  uids, but is also localized on the cell surface 
and/or extracellular matrix (  Clemmons, 2001  ). In this study, we 
have provided two lines of independent evidence indicating that 
abundant amounts of intact IGFBP-5 is indeed located on the sur-
face of differentiating myoblasts and is capable of IGF binding. 
It is possible that cell-surface associated IGFBP-5 provides a means 
of attracting IGF-II to the close proximity of the IGF-IR receptor, 
thereby enhancing IGF-II signaling activity and initiating the 
IGF-II positive auto-regulation loop. 
  In summary, we have uncovered a novel mechanism by 
which the induction of IGFBP-5 promotes the myogenic action 
of autocrine IGF-II. We provide evidence suggesting that IGFBP-5 
is located on the cell surface and binds to autocrine IGF-II and 
potentiates its interaction with IGF-IR, leading to the enhanced 
activation of the IGF-IR-PI3K-Akt signaling activity and a fur-
ther increase in IGF-II gene expression. An accelerated activation 
of this auto-regulatory loop stimulates muscle cell differentia-
tion after reaching a certain threshold. We have extended these 
fi  ndings to primary cultures, suggesting that this mechanism is 
of physiological relevance. 
  Materials and methods 
  Materials and animals 
  Monoclonal MHC antibody (MF20) was purchased from the Developmen-
tal Studies Hybridoma Bank (Iowa City, IA). Antibodies against MyoD 
(M-318) and Myogenin (M-225) were purchased from Santa Cruz Bio-
technology, Inc., and antibodies to Akt and phospho-Akt (Ser473) were from 
Cell Signaling Technology. Monoclonal anti-tubulin antibody (T6793) was 
from Sigma-Aldrich. The secondary antibody conjugates were purchased 
from Jackson ImmunoResearch Laboratories. Recombinant human IGF-I, 
IGF-II, Des(1-6)IGF-II, and IGFBP-5 were purchased from GroPep. Mutant 
IGFBP-5 with reduced afﬁ  nity for IGF was provided by Dr. David Clemmons 
(University of North Carolina at Chapel Hill;   Imai et al., 2000  ). Trypsin, 
fetal bovine serum (FBS), horse serum (HS), DMEM, OPTI-minimum essen-
tial medium, and penicillin-streptomycin were purchased from Invitrogen. 
The BCA protein assay kit was purchased from Thermo Fisher Scientiﬁ  c. 
Reagents for enhanced chemiﬂ  uorescence were obtained from GE Health-
care. The Dual-luciferase reporter assay kit was from Promega. TriPure 
  Isolation Reagent was from Roche. Oligonucleotide primers for PCR 
were purchased from Invitrogen. iQ SYBR Green Supermix was from Bio-JCB • VOLUME 182 • NUMBER 5 • 2008  990 
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The speciﬁ  city of the PCR was veriﬁ  ed by denaturing curve analysis and 
direct sequencing of the products. 
  Immunohistochemistry 
  Cells cultured on 6-well dishes were washed twice with 1x PBS before ﬁ  xa-
tion in 4% paraformaldehyde for 10 min. Cells were permeabilized for 
5 min in 1x PBS containing 0.2% Triton X-100 (PBST), washed twice with 
PBST, and incubated with primary antibodies at 4  °  C overnight. The cells 
were next washed three times with PBST before incubation with Cy3-conju-
gated secondary antibodies for 2 h at room temperature. For experiments 
that required intact membrane integrity, staining was performed in 1x PBS 
without detergent. Immunoﬂ  uorescence or phase-contrast images were ob-
tained at room temperature using a microscope (Eclipse E600; Nikon) with 
Plan Fluor 10x/0.3 or 20x/0.5 dry objectives. Images were acquired 
using a camera (DC50NN; Nikon) and Scion acquisition software. Images 
were processed with Photoshop for overlay. A Leica SP5 microscope with 
HCX PL APO CS 40.0  ×  /0.85 dry objective was used for confocal imaging 
at room temperature. Images were acquired and processed using LAS AF 
software (Leica) with background subtraction for some images. Nucleus 
was stained with DAPI. Differentiation index (%) was quantiﬁ  ed as the per-
centage of MHC-positive nuclei over total nuclei number. 
  Western and ligand blot analysis 
  Equal amounts of protein were separated by SDS-PAGE and transferred to 
Immobilon P membranes (Millipore) and subjected to Western blot follow-
ing published procedures (  Duan et al., 1996  ). The antibodies were used at 
concentrations recommended by the commercial sources. Ligand blot anal-
ysis was performed using digoxigenin-labeled IGF-I following published 
procedure (  Yin et al., 2004  ). To determine cell surface  –  bound IGFBP-5, 
cultured cells were washed in 1x PBS twice and then incubated brieﬂ  y in a 
high salt buffer (2N NaCl). 
  Luciferase reporter assay 
  The transcription activity of Myogenin was determined using the dual lucif-
erase reporter assay kit (Promega). In brief, myoblasts were cotransfected 
with pCS2MTmyogenin or pCS2 plasmid, 4RTK or control minimal TK re-
porter, and an internal control vector encoding   Renilla   luciferase. Differen-
tiation was induced 1 d after transfection. 2 d after inducing differentiation, 
cells were washed, and cell lysates were used to measure the ﬁ  reﬂ  y and 
  Renilla   luciferase activities. The result was expressed as fold change over 
the empty control vector and 4RTK transfected group. Transfection efﬁ  ciency 
was normalized by   Renilla   luciferase activity. 
  Statistical analysis 
  Differences among groups were analyzed by   t   test or one-way analysis 
of variance followed by Tukey post test, using Prizm (GraphPad Soft-
ware, Inc.). Signiﬁ  cance was accepted at P   <   0.05. 
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